North America
North America is a dominant market for renal denervation, primarily driven by the increasing prevalence of hypertension and the growing need for effective treatment options. The U.S. holds a significant share of the market due to high healthcare awareness, advanced medical infrastructure, and the rising adoption of minimally invasive procedures. With the FDA’s approval of...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian